Our vision is to be a world-class commercial biotechnology company. We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries. More >>

EXEL (Common Stock) Exchange NASDAQ (US Dollar) Price $4.72 Change (%)   0.18 (3.67%) Volume 676,210 Data as of 07/02/09 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Date Title   06/16/09 Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference 06/04/09 Exelixis Announces June 9 Webcast of Presentation at the Goldman Sachs Thirtieth Annual Healthcare Conference 06/01/09 Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR 06/01/09 Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K

2008 Annual Report (pdf) 2008 Form 10-K (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.